glp-1 employer coverage news october 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Employers Take a Variety of

In the wake of the Trump deal, the GLP-1 market is poised to evolve with broader adoption of oral formulations, ongoing price competition, and more payer-level formulary adjustments that will influence long-term affordability and access

Its purpose is to let your body acclimate to the medication, not to produce significant weight loss

While semaglutide offers superior results, it is not without potential side effects, such as gastrointestinal discomfort, and may not be suitable or accessible for everyone

The side effect profiles of these medications reflect their distinct mechanisms of action and help guide patient selection